SK Capital secures financing to buy Apotex Pharmaceutical Group

2023-07-19T12:38:00
Mexico
Cuatrecasas advises on financing for approximately USD 13.5 million for the acquisition of the Apotex Pharmaceutical Group by the firm SK Capital
SK Capital secures financing to buy Apotex Pharmaceutical Group
July 19, 2023
Cuatrecasas has advised a syndicate of financial institutions—led by the Bank of Nova Scotia, RBC Capital Markets, TD Securities, HSBC Securities (USA), Truist Securities, Fédération des caisses Desjardins du Québec and MUFG Bank Canada, as joint lead arrangers—on aspects of Mexican law on financing for approximately USD 13.5 million for the acquisition of the Apotex Pharmaceutical Group by US private equity firm SK Capital.

Apotex is a Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. The company employs nearly 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex exports to over 100 countries and regions, and operates in over 45 countries, with a significant presence in Canada, the United States, Mexico, and India.

The Cuatrecasas Mexico City team advising on this transaction was led by our partner León López with the support of lawyers Alberto de Villa and Ivana Muñiz.

July 19, 2023